Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | IDH2 | P48735 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.37 |
| ▸ | EED | O75530 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | GRK6 | P43250 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20103431 | 0.85 | ESR2 (0.46) | ESR2SLC6A4KDM1AMAPTCCNT1 | |
| SCHEMBL31638693 | 0.84 | ESR2 (0.43) | ESR2SLC6A4MAPTCYP26A1MTNR1B | |
| SCHEMBL31638726 | 0.84 | ESR2 (0.43) | ESR2IDH2SLC6A4EEDMAPT | |
| SCHEMBL20103422 | 0.83 | SLC6A4 (0.44) | IDH2SLC6A4FFAR1KDM1ACCNT1 | |
| SCHEMBL31638831 | 0.81 | ESR2 (0.43) | ESR2SLC6A4MAPTCYP26A1 | |
| SCHEMBL20103515 | 0.81 | ESR2 (0.47) | ESR2CCNT1CDK9 | |
| SCHEMBL20103308 | 0.78 | CCNT1 (0.42) | ESR2FFAR1CCNT1CDK9 | |
| SCHEMBL24646677 | 0.78 | IDH2 (0.41) | IDH2SLC6A4MAPTCCNT1CDK9 | |
| SCHEMBL20103466 | 0.76 | CDK9 (0.46) | MAPTCCNT1CDK9MTNR1BL3MBTL1 | |
| SCHEMBL12738759 | 0.76 | ESR2 (0.39) | ESR2SLC6A4FFAR1CYP26A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220226298-A1 | GPR40 AGONISTS | KALLYOPE, INC. | 2022-07-21 | — | — | US | disclosed |
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-27 | — | — | US | disclosed |
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-27 | — | — | US | disclosed |
| WO-2020242943-A1 | GPR40 AGONISTS | KALLYOPE, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2020-02-06 | — | — | US | disclosed |
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2020-02-06 | — | — | US | disclosed |
| WO-2018081047-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226298-A1 | GPR40 AGONISTS | GPR119, GPR65, GLP1R | ESR2 552/4885IDH2 1690/4885SLC6A4 596/4885 |
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR55 | ESR2 97/4885IDH2 4099/4885SLC6A4 3848/4885 |
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | GPR119, GPR65, GPR55 | ESR2 97/4885IDH2 4099/4885SLC6A4 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.